Notable Quotes

"STEM's spinal program has a good chance of success."
(7/29/15)
StemCells Inc.
-
The Life Sciences Report Interview with Caroline Corner
More >

"AEMD has approved products that remove viruses, and is now also targeting breast cancer."
(7/29/15)
Aethlon Medical Inc.
-
The Life Sciences Report Interview with Caroline Corner
More >

"Development of AEMD's Hemopurifier continues to ramp up, and results to date look very encouraging."
(7/15/15)
Aethlon Medical Inc.
-
The Life Sciences Report Interview with Brian Marckx
More >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today."
(7/8/15)
Cynapsus Therapeutics Inc.
-
The Life Sciences Report Interview with Jason Napodano
More >

"We believe RGS has the potential to become Australia's next success story in regenerative medicine."
(7/1/15)
Regeneus Ltd.
-
The Life Sciences Report Interview with Marcel Wijma
More >

Streetwise Interviews

Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and Diagnostics Deliver Drugs and Profits
Source: George S. Mack of The Life Sciences Report (7/29/15)
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. In this interview with The Life Sciences Report, Corner brings important names to investors' attention.
More >

Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities
Source: George S. Mack of The Life Sciences Report (7/22/15)
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.
More >

Four Small-Cap Medtechs Primed for Outsize Returns: Zacks' Brian Marckx
Source: Staff of The Life Sciences Report (7/15/15)
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement. In this interview, Brian Marckx, senior medical device/diagnostics analyst with Zacks Investment Research, tells The Life Sciences Report how that situation is changing and identifies some innovative companies poised to make the most of the situation.
More >

Zacks' Jason Napodano Is Not Focused on a Biotech Bubble
Source: George S. Mack of The Life Sciences Report (7/8/15)
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies. In this interview with The Life Sciences Report, Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.
More >

Probe Biotech's Diverse Subsectors for Undervalued Companies: Van Leeuwenhoeck's Marcel Wijma
Source: Gail Dutton of The Life Sciences Report (7/1/15)
The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront.
More >

A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals
Source: George S. Mack of The Life Sciences Report (6/24/15)
What a difference just nine months can make. NovaBay Pharmaceuticals Inc. has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014. In this interview with The Life Sciences Report, company founder, President and CEO Dr. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve.
More >

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading
Source: George S. Mack of The Life Sciences Report (6/24/15)
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report, Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two.
More >

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners
Source: George S. Mack of The Life Sciences Report (6/17/15)
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth.
More >

The Big Picture: Edison's Pooya Hemami Looks Beyond Cancer for Biotech Winners
Source: Peter Byrne of The Life Sciences Report (6/10/15)
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health. In this interview with The Life Sciences Report, Dr. Hemami reflects on the biotech market at midyear, and describes a robust basket of outstanding companies with pipeline treasures.
More >

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next
Source: George S. Mack of The Life Sciences Report (5/27/15)
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over.
More >

ContraVir Pharmaceuticals Brandishes a New Weapon in Biotech's Antiviral Wars
Source: Peter Byrne of The Life Sciences Report (5/27/15)
Nobody understands the ins and outs of the antivirals better than the CEO of ContraVir Pharmaceuticals, and James Sapirstein unfolds the backstory behind the creation of his newest venture in this interview with The Life Sciences Report. Millions of patients around the globe await the unveiling of the company's emerging pipeline products targeting the viruses that cause shingles and hepatitis B—products that also promise opportunity to biotech investors.
More >

BrainStorm Cell Therapeutics Tackles Neurodegenerative Disease with Super Cells
Source: Peter Byrne of The Life Sciences Report (5/20/15)
An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). Dr. Tony Fiorino, the U.S.-based CEO of BrainStorm Cell Therapeutics Inc., tells The Life Sciences Reporthow his company is winning over American investors with a revolutionary, university lab-backed cell therapy.
More >

Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant
Source: George S. Mack of The Life Sciences Report (5/12/15)
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
More >

The Barbell Approach Builds Powerful Healthcare Stocks: StoneCastle's Bruce Campbell
Source: George S. Mack of The Life Sciences Report (5/6/15)
Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments. He looks for companies that are strong and balanced, with muscular organic growth on one side and healthy acquisitions on the other. In this interview with The Life Sciences Report, the founder and president of Canada-based StoneCastle Investment Management spotlights six names that have proven themselves with good runs but have potential for much bigger gains.
More >

How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM
Source: George S. Mack of The Life Sciences Report (4/23/15)
There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and investors to grow stem cell and regenerative medicine companies from the ground up. In this interview with The Life Sciences Report, CCRM President and CEO Michael May guides us through the process that brings ideas out of academia and adds the essential nurturing elements to get startups off the ground and into commercial development. Along the way, he mentions a few names that may interest investors.
More >

How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey
Source: George S. Mack of The Life Sciences Report (4/16/15)
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of resource commodities declines, investors are diverting investment capital to healthcare stocks, especially in the medical technology sector. In this interview with The Life Sciences Report, Storey presents three names that don't come close to their long-term fair valuation potential. The upside, he believes, could be quite dramatic.
More >

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Source: George S. Mack of The Life Sciences Report (4/8/15)
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience. Jason Kolbert of New York City-based Maxim Group relishes finding early-stage, cutting-edge, small-cap names that he believes will change the paradigm of medical practice. In this interview with The Life Sciences Report, Kolbert shares a list of favorite biotechs developing products that will command premium pricing and sustained performance in the marketplace.
More >

More Experts

"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels."
(7/8/15)
Resverlogix Corp.
-
The Life Sciences Report Interview with Jason Napodano
More >

"RVX may have the answer to developing a new generation of cardio drugs."
(7/1/15)
Resverlogix Corp.
-
The Life Sciences Report Interview with Marcel Wijma
More >

"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases."
(6/24/15)
Inovio Pharmaceuticals Inc.
-
The Life Sciences Report Interview with George Zavoico
More >